Possibilities of therapy GLP1 RA for diabetics with nephropathy

Czech version

Authors: Alena Adamíková
Authors‘ workplace: Diabetologické centrum Interní kliniky Krajské nemocnice T. Bati, a. s., Zlín, přednosta MUDr. Jiří Latta
Published in: Vnitř Lék 2015; 61(4): 312-315
Category: Reviews

Overview

The incretin hormone GLP1 (glucagon-like peptide 1) has also systemic effects besides its effects on the pancreas. The renal expression for the receptors GLP1 and DPP4 has been described in a whole line of experimental studies. Activation of the receptors for GLP1 in the kidneys has diuretic and natriuretic effects apparently through the renal tubular cells and sodium transporters. Pre-clinical incretin therapy decreased albuminuria, affected glomerulosclerosis, oxidative stress and fibrosis in the kidneys. Diabetic nephropathy is the major cause of kidney failure. In the course of renal insufficiency the functional possibilities and simultaneous safe compensation of diabetes are limited. The treatment GLP1 RA of patients with type 2 diabetes and nephropathy appear to be effective from the aspect of effectiveness and safety.

Keywords:
diabetes mellitus – GLP1 RA – nephropathy

Sources

1. Körner M, Stöckli M, Waser B et al. GLP1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med 2007; 48(5): 736–743.

2. Websky K, Reichetzeder Ch, Hocher B. Physiology and pathophysiology of incretins in the kidney. Curr Opin Nephrol Hypertens 2014; 23(1): 54–60. Dostupné z DOI: <http://dx.doi.org/10.1097/01.mnh.0000437542.77175.a0>.

3. Gutzwiller JP, Hruz P, Huber AR et al. Glucagon-like peptid 1 is involved in sodium and water homeostasis in humans. Digestion 2006; 73(2–3): 142–150.

4. Kodera R, Shikata K, Kataoka HU et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54(4): 965–978.

5. Lau CWD, Wilding J, Astrup A et al. Liraglutide 3.0 mg improves insulin secretion and action in overweight/obese adults without type 2 diabetes: the SCALE Obesity and Prediabets trial. Diabetologia 2014; 57(Suppl 1): P881.

6. Davidson JA, Brett J, Falahati A et al. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011; 17(3): 345–355.

7. Umpierrez G, Atkin S, Bain S et al. Efficacy and safety of liraglutide versus placebo in subjects with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomised trial. Diabetologia 2014; 57(Suppl 1): Abstract 181.

8. SPC Victoza. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/001026/WC500050017.pdf>.

9. SPC Lyxumia. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002445/WC500140401.pdf>.

10. Adamíková A. Lixisenatid. Remedia 2014; 24(2): 68–72.

11. Leiter LA, Gómez-Huelgas R, Ambos A et al. Lixisenatide is effective and well tolerated in patients with type 2 diabetes mellitus and renal impairment. Abstract. Can J Diabetes 2014; 38(5): S10-S11.

12. Linnebjerg H, Kothare PA, Park S et al. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64(3): 317–327.

13. SPC Bydureon. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/002020/WC500108241.pdf>.

14. Marbury TC, Flin A, Segel S et al. Pharmacokinetics and tolerability of a single dose of semaglutide, a once-weekly human GLP1 analogue, in subjects with and without renal impairment. Diabetologia 2014; 57(Suppl 1): P882.

15. Leiter L, Carr MC, Stewart M et al. HARMONY 8: once-weekly glucagon-like peptide 1 receptor agonist albiglutide vs sitagliptin for patients with type 2 diabetes with renal impairment:week 26 results. Diabetologia 2013; 56(Suppl 1): P070.

16. Tofe Povedano S, Dungan KM, Forst T et al. Efficacy and safety of once weekly dulaglutide versus once daily liraglutide in type 2 diabetes (AWARD-6). Diabetologia 2014; 57(Suppl 1): P40.

17. Kang J, Choi S, Choi I et al. HM11260C, a new generation long acting GLP1 R agonist with a unique pharmacokinetic profile improves glucose control and GI tolerability; a phase IIa clicical trial in type 2 diabetes mellitus. Diabetologia 2013; 56(Suppl 1): P080.

18. Vachek J, Tesař V. Diabetická nefropatie. In: Karen I, Svačina Š (eds). Diabetes mellitus v primární péči. 2nd ed. Axonite CZ: Praha 2014: 64–71. ISBN 978–80–904899–8–1.